Inge T H, Hoover S K, Susskind B M, Barrett S K, Bear H D
Department of Microbiology and Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
Cancer Res. 1992 Mar 15;52(6):1386-92.
Transforming growth factor beta (TGF-beta) is a potent immunosuppressive cytokine that is produced by neoplastic and normal cells. It has not been demonstrated directly, however, that TGF-beta can inhibit antigen-specific T-cell responses to tumor cells in vitro. We show here that generation of antitumor cytotoxic T-lymphocyte (CTL) activity in mixed-lymphocyte tumor cultures of splenocytes from DBA/2 mice immunized with the syngeneic P815 mastocytoma + Corynebacterium parvum was consistently and profoundly inhibited when 0.675 to 10 ng/ml of TGF-beta were added on Day 0 of culture. TGF-beta added on Day 1 or later had little or no effect. In contrast to the results with P815 immune mice, mixed-lymphocyte tumor cultures established with splenocytes from P815 tumor-bearing hosts showed variable degrees of inhibition by TGF-beta, depending on the stage of the ongoing in vivo immune response. Addition of recombinant murine tumor necrosis factor alpha (1,000 or 10,000 units/ml) partially reversed inhibition of CTL responses by TGF-beta, while recombinant interleukin 2 nearly completely reversed the suppression. These data indicate that one level at which TGF-beta may act to inhibit mixed-lymphocyte tumor cultures is that of cytokine production. To determine whether TGF-beta also has any direct effect on CTL, P815-specific CTL clones derived from tumor-bearing host mice were utilized. We found that proliferation of rested CTL clones in response to tumor cells + interleukin 2 was inhibited by 5 ng/ml of TGF-beta, while the interleukin 2-dependent reactivation of cytolytic activity was not affected by TGF-beta. In contrast to rested CTL, when TGF-beta was added to cultures of previously activated CTL, proliferation was not inhibited. These data demonstrate that TGF-beta has profound inhibitory effects on the in vitro generation of effector CTL from tumor-specific murine splenocytes, and this inhibition may be an indirect result of suppressed cytokine production as well as a direct antiproliferative effect on CTL.
转化生长因子β(TGF-β)是一种由肿瘤细胞和正常细胞产生的强效免疫抑制细胞因子。然而,尚未直接证明TGF-β能在体外抑制抗原特异性T细胞对肿瘤细胞的反应。我们在此表明,在用同基因P815肥大细胞瘤+微小棒状杆菌免疫的DBA/2小鼠的脾细胞混合淋巴细胞肿瘤培养物中,当在培养第0天添加0.675至10 ng/ml的TGF-β时,抗肿瘤细胞毒性T淋巴细胞(CTL)活性的产生持续且显著受到抑制。在第1天或之后添加TGF-β几乎没有影响。与P815免疫小鼠的结果相反,用P815荷瘤宿主的脾细胞建立的混合淋巴细胞肿瘤培养物显示,TGF-β的抑制程度各不相同,这取决于体内正在进行的免疫反应阶段。添加重组小鼠肿瘤坏死因子α(1000或10000单位/ml)可部分逆转TGF-β对CTL反应的抑制,而重组白细胞介素2几乎可完全逆转这种抑制。这些数据表明,TGF-β抑制混合淋巴细胞肿瘤培养物的一个作用水平是细胞因子产生水平。为了确定TGF-β是否也对CTL有直接作用,我们利用了从荷瘤宿主小鼠中获得的P815特异性CTL克隆。我们发现,5 ng/ml的TGF-β可抑制静息CTL克隆对肿瘤细胞+白细胞介素2的增殖反应,而白细胞介素2依赖性的溶细胞活性再激活不受TGF-β影响。与静息CTL相反,当将TGF-β添加到先前激活的CTL培养物中时,增殖未受抑制。这些数据表明,TGF-β对肿瘤特异性小鼠脾细胞体外产生效应CTL具有显著的抑制作用,这种抑制可能是细胞因子产生受抑的间接结果以及对CTL的直接抗增殖作用。